Telethonin-related limb-girdle muscular dystrophy R7 is a rare, inherited muscle disease. It mainly weakens the muscles around the hips and shoulders. It happens when both copies of a gene called TCAP do not work properly. TCAP makes a small muscle protein called telethonin (also called titin-cap). Telethonin sits at the Z-disc of the muscle fiber. It helps anchor titin, a giant protein, so the muscle fiber can hold together and sense stretch. When telethonin is missing or broken, the muscle fiber becomes fragile, signals are disturbed, and fibers slowly break down. That is why weakness and muscle wasting grow over time. PMC+2PLOS+2

Telethonin-related limb-girdle muscular dystrophy R7 (LGMDR7) is a rare, inherited muscle disease caused by harmful changes in the TCAP gene, which makes a small protein called telethonin. Telethonin sits at the Z-disc of skeletal and heart muscle fibers and helps keep the muscle’s contractile machinery aligned and healthy. When telethonin is missing or abnormal, muscles of the hips, thighs, shoulders and upper arms become weak over time; some people may also have heart muscle involvement. LGMDR7 is autosomal recessive, which means a person is affected when they inherit two non-working copies of TCAP. PMC+2ScienceDirect+2

 LGMDR7 usually starts in late childhood or the teen years with hip and shoulder weakness, difficulty running or climbing stairs, and may later involve some distal muscles (lower legs). Calf enlargement and early hamstring/gluteal changes on MRI can be seen; blood tests often show high CK (creatine kinase). Some families report heart changes, so periodic cardiology checks are important. NCBI+2BioMed Central+2

Telethonin binds to titin (another structural protein) to keep the Z-disc stable. Studies in cells and animals show that TCAP loss disrupts sarcomere stability, increases mechanical stress, and can disturb heart muscle biology. This explains why a few people with TCAP variants develop cardiomyopathy. PMC+1

LGMDR7 is rare worldwide. Early reports came from families in Brazil, but cases are now described in many countries. Onset is often in the first or second decade, but milder or later cases also exist. PMC+2malacards.org+2

---

Other names

• LGMDR7 (telethonin-related) – the current name in the updated LGMD system (R = recessive; “7” is the subtype number). PMC

• LGMD2G – the older name you will still see in many papers. PMC

• TCAP-related LGMD or telethonin deficiency myopathy – descriptive names used in studies. PMC

(In experts changed the naming rules to use “LGMDR” for recessive forms; that is why “LGMD2G” became “LGMDR7.”) PMC+1

---

Types

LGMDR7 is one disease, but the pattern and speed can vary. Doctors often describe three broad patterns:

1. Classic limb-girdle pattern. Slow, symmetrical weakness of the hips and thighs first, then the shoulders and upper arms. Calf muscles may look big. Walking becomes harder over years. PMC+1

2. Disto-proximal lower-limb pattern. Early weakness of tibialis anterior (front of shin) causes foot-drop and tripping; hip and thigh weakness follow. PubMed

3. Mild/asymptomatic hyperCKemia pattern. Some people feel well or only slightly weak but have high blood CK and a typical genetic result; MRI may show a characteristic pattern with relative sparing of the sartorius muscle. ResearchGate

Heart and breathing problems are uncommon but reported in a few patients and animal/functional studies suggest telethonin also has roles in cardiac muscle. Doctors therefore screen the heart as a precaution. ScienceDirect+1

---

Causes

The root cause is pathogenic variants in TCAP (both copies changed), which lead to too little or non-working telethonin in muscle. Below are the key genetic and biological contributors that explain “what causes it” and “what makes it worse or different from person to person”:

1. Loss-of-function TCAP variants (nonsense/frameshift) → no functional telethonin. PLOS

2. Missense TCAP variants that change telethonin’s shape and binding. ScienceDirect

3. Splice-site TCAP variants that disrupt mRNA processing. PMC

4. Compound heterozygosity (two different TCAP variants, one from each parent). PLOS

5. Founder variants in certain populations (explains family clusters). PMC

6. Telethonin–titin anchoring failure at the Z-disc → structural fragility. anatomypubs.onlinelibrary.wiley.com

7. Sarcomere assembly defects (myofibrillogenesis is impaired). PMC

8. Faulty stretch/mechanosensing signals inside muscle fibers. Frontiers

9. p53 pathway dysregulation under mechanical stress (pro-apoptotic signaling). AHA Journals

10. T-tubule/sarcomere cross-talk changes that reduce contraction efficiency. ScienceDirect

11. Secondary muscle fiber necrosis and regeneration cycles in dystrophy. BioMed Central

12. CK leakage due to membrane instability (biochemical marker of damage). MedlinePlus

13. Modifier genes in other Z-disc proteins (e.g., titin/alpha-actinin) that can shape severity. Frontiers

14. Age at onset (earlier onset often means faster progression). malacards.org

15. Muscle use and micro-injury during daily activity (not a cause of the disease, but can accelerate weakness in fragile fibers). BioMed Central

16. Intercurrent illness or deconditioning (temporary worsening). BioMed Central

17. Poor nutrition or low protein intake (can limit muscle repair; supportive factor). BioMed Central

18. Delayed diagnosis (missed physio and safety advice may allow faster decline). BioMed Central

19. Infrequent heart surveillance (rare cardiac issues may go unnoticed and add disability). ScienceDirect

20. Lack of access to mobility aids/therapy (increases falls and disuse). BioMed Central

---

Common symptoms

1. Tiring legs and hip weakness. Climbing stairs or rising from the floor becomes hard; this is the classic first sign. Medscape

2. Waddling or swaying walk. Pelvic muscles cannot stabilize the trunk well. Medscape

3. Trouble running or jumping. Power muscles fatigue quickly. MedlinePlus

4. Foot-drop and frequent tripping. Weak shin muscles (tibialis anterior). PubMed

5. Big-looking calves. Calf hypertrophy from muscle changes and fat replacement. PMC

6. Using hands to rise (Gowers’ sign). You “climb” your thighs to stand. Medscape

7. Shoulder weakness. Lifting above the head becomes hard. MedlinePlus

8. Scapular winging. Shoulder blades stick out with arm movement. Medscape

9. Muscle cramps or aches after activity. Fragile fibers get irritated. BioMed Central

10. Falls and poor balance. Hips and ankles cannot protect the step. Medscape

11. Low endurance. Walking distance slowly shrinks over years. BioMed Central

12. Tight hamstrings or Achilles tendons. Contractures from imbalance/inactivity. BioMed Central

13. Breathing weakness (rare, usually mild). Shortness of breath on exertion possible in some. BioMed Central

14. Heart symptoms (uncommon). Palpitations or reduced pumping strength can occur in a few; most patients are heart-healthy but should be checked. ScienceDirect

15. Silent high CK on a blood test. Sometimes the only clue early on. MedlinePlus

---

Diagnostic tests

A) Physical examination

1. Pattern-focused strength testing. The doctor checks hips, thighs, and shoulders in a set order. A “proximal-greater-than-distal” pattern fits LGMD. This helps separate muscular dystrophy from nerve disease. Medscape

2. Gowers’ maneuver and rise-from-chair test. Needing your hands to stand suggests proximal weakness. Timing the movement tracks change over time. Medscape

3. Gait observation and balance tests. Waddling gait, toe-walking from tight calves, or foot-drop from weak shins point doctors to specific muscles. Medscape

4. Look for muscle bulk and scapular winging. Calf enlargement and winging shoulders support a limb-girdle pattern and guide which genes to test. PMC

B) Manual / functional bedside tests

5. Manual Muscle Testing (MRC scale). Hands-on grading (0–5) documents strength in each muscle group and monitors change. Medscape

6. Timed tests (e.g., 10-meter walk, 6-minute walk). Simple stop-watch measures show endurance and safety in daily life. BioMed Central

7. Foot-drop checks (heel-walk, step-up). Testing ankle dorsiflexion quickly screens for tibialis anterior weakness common in this subtype. PubMed

8. Respiratory bedside measures (peak cough flow). Quick clinic checks can flag early breathing weakness and cue full lung tests. BioMed Central

C) Laboratory & pathological tests

9. Serum creatine kinase (CK). CK is often high, sometimes very high, even before big symptoms. It shows muscle membrane leakiness. malacards.org

10. Next-generation sequencing (gene panel or exome). Confirms TCAP variants and rules out other LGMD genes. Genetic testing is the diagnostic gold standard today. BioMed Central

11. Variant classification and parental testing. Checking parents helps prove recessive inheritance (two faulty copies in the patient). PMC

12. Muscle biopsy (light microscopy). Shows a dystrophic pattern: fiber size variation, necrosis, and fibrosis—typical for LGMD. BioMed Central

13. Immunohistochemistry / Western blot for telethonin. Staining or blotting can show reduced/absent telethonin protein, supporting a TCAP diagnosis. BioMed Central

14. Urine myoglobin (when acutely sore/weak). A spike after heavy activity can reflect muscle breakdown; it is not specific but supports muscle injury. MedlinePlus

D) Electrodiagnostic & cardiopulmonary tests

15. Electromyography (EMG). Shows a myopathic pattern (small, short-duration motor units) rather than nerve damage. Helps rule out neuropathies. Medscape

16. Nerve conduction studies (NCS). Usually normal in muscular dystrophy; confirms the problem is muscle, not nerve. Medscape

17. Heart checks (ECG and echocardiogram). Most people with LGMDR7 have normal results, but screening is wise because telethonin has roles in heart muscle and rare cardiac issues can occur. ScienceDirect

E) Imaging tests

18. Muscle MRI of thighs and calves. MRI maps which muscles are replaced by fat. In LGMDR7, reports describe relative sparing of the sartorius muscle—this pattern can support the diagnosis. ResearchGate

19. Cardiac MRI (if echo suggests changes). Gives a more detailed look at the heart muscle when needed. ScienceDirect

20. Muscle ultrasound (clinic-friendly). Quick, painless scan to follow fat replacement and guide where to biopsy. BioMed Central

Non-pharmacological treatments (therapies & others)

There is no disease-specific cure yet. Care focuses on strength, flexibility, breathing, and heart health using proven, safe strategies.

1. Personalized physical therapy (PT): gentle, regular, sub-maximal strengthening and stretching to maintain function and slow contractures; avoid painful overexertion. renaissance.stonybrookmedicine.edu

2. Home exercise plan: low-impact aerobic work (walking, cycling in moderation) to support cardiovascular fitness without muscle damage. renaissance.stonybrookmedicine.edu

3. Contracture management: daily calf/Achilles and hip flexor stretches; night splints if needed. renaissance.stonybrookmedicine.edu

4. Orthoses and mobility aids: ankle-foot orthoses for foot-drop, canes/rollators or wheelchairs for safety and endurance. renaissance.stonybrookmedicine.edu

5. Respiratory surveillance: baseline and 6–12-monthly spirometry, peak cough flow, and sleep assessments in progressive disease. chestnet.org+1

6. Airway clearance: manual techniques or assisted cough devices when peak cough is low to prevent infections. journal.chestnet.org

7. Non-invasive ventilation (NIV): start when tests show chronic hypoventilation or symptoms (morning headaches, daytime sleepiness); improves symptoms and reduces hospitalizations. journal.chestnet.org

8. Cardiac monitoring: regular ECG/echo and prompt evaluation of palpitations or syncope to prevent sudden events. PMC

9. Scoliosis care: early PT, posture support; surgical referral if curves become severe and impair breathing or sitting. renaissance.stonybrookmedicine.edu

10. Falls prevention: home safety review, balance work, adequate lighting, and footwear. renaissance.stonybrookmedicine.edu

11. Energy conservation & pacing: activity distribution through the day to reduce over-fatigue and falls. renaissance.stonybrookmedicine.edu

12. Nutrition optimization: adequate protein, calories, and vitamin D; address swallowing issues early. PMC

13. Vaccinations: influenza and pneumococcal vaccines reduce respiratory complications in neuromuscular disease. journal.chestnet.org

14. Mental health support: coping strategies, counseling, and peer groups to help with chronic disease stress. National Organization for Rare Disorders

15. School/work accommodations: mobility access, rest breaks, and ergonomic adjustments to remain engaged. National Organization for Rare Disorders

16. Pain and cramp self-care: hydration, gentle heat, and guided stretching rather than unsupervised intense workouts. renaissance.stonybrookmedicine.edu

17. Sleep hygiene: consistent schedules; early evaluation for snoring or morning headaches (possible hypoventilation). journal.chestnet.org

18. Genetic counseling: for family planning and carrier testing. MedlinePlus

19. Clinical-trial awareness: ask about studies targeting LGMD pathways. Muscular Dystrophy Association

20. Care coordination: neuromuscular, rehab, respiratory, and cardiology teams working together improves outcomes. PMC

---

Drug treatments

Important: No drug is FDA-approved specifically for LGMDR7. Medicines below are commonly used for heart failure/cardiomyopathy, arrhythmias, edema, or symptom support when those problems occur. Always follow your cardiologist/neuromuscular specialist’s advice.

Heart failure guideline-directed therapy (choose based on your cardiologist’s plan):

1. Sacubitril/valsartan (Entresto)—ARNI that lowers HF hospitalizations and CV death; typical dose titrated to target as tolerated. Watch BP and kidney function. PMC

2. ACE inhibitor (e.g., lisinopril)—improves symptoms and survival in HFrEF; dose titrated; monitor potassium/creatinine. (FDA label example for metoprolol below; ACE labels are on accessdata; HF guidance cited.) AHA Journals

3. ARB (e.g., losartan/Cozaar)—alternative when ACEI not tolerated; avoid in pregnancy; monitor kidneys and potassium. FDA Access Data

4. Evidence beta-blocker (metoprolol succinate ER/Toprol-XL)—reduces HF hospitalizations/mortality; start low, go slow. FDA Access Data

5. Mineralocorticoid receptor antagonist (spironolactone/Aldactazide or eplerenone/Inspra)—improves survival in selected HF; watch for hyperkalemia. FDA Access Data+1

6. Loop diuretic (furosemide/Lasix; torsemide/Demadex/Soaanz)—relieves swelling and breathlessness from fluid; adjust to symptoms; monitor electrolytes. FDA Access Data+2FDA Access Data+2

7. SGLT2 inhibitor (dapagliflozin/Farxiga or empagliflozin/Jardiance)—reduces HF hospitalization and CV death across EF ranges; dose usually 10 mg daily (dapagliflozin). FDA Access Data+1

8. Ivabradine (Corlanor)—slows heart rate in HFrEF patients in sinus rhythm with elevated resting HR despite beta-blocker; reduces HF hospitalization. FDA Access Data

Arrhythmias and rate/rhythm control (specialist use):

1. Amiodarone—for life-threatening ventricular arrhythmias; requires careful monitoring (lungs, thyroid, liver). FDA Access Data+1
2. Digoxin (Lanoxin)—for symptom relief and rate control in selected HF/AF; narrow therapeutic window; monitor levels. FDA Access Data
3. Anticoagulation (apixaban/Eliquis)—for stroke prevention in atrial fibrillation when indicated. FDA Access Data

Additional symptom-directed medications (individualized):

1. Torsemide (tablet or modern brands)—alternative loop diuretic with good oral bioavailability. FDA Access Data
2. Furosemide injection / FUROSCIX (subcutaneous)—for outpatient decongestion in selected HF patients per label. FDA Access Data+1
3. Potassium and magnesium repletion—often needed when on diuretics; dose and product per clinician; monitor labs (use HF guideline for principle). PMC
4. Pain control (e.g., prescription-strength ibuprofen/naproxen)—short courses for musculoskeletal pain only if heart/kidney status allows and with stomach protection; check individual FDA labels. (Use sparingly in HF.) PMC
5. Vaccines (influenza, pneumococcal)—not “drugs” but essential biologics to cut respiratory complications in neuromuscular disease. journal.chestnet.org
6. Short-term antibiotics for chest infections—per culture/suspected pathogen; avoid agents that worsen QT if on amiodarone. (Label examples show QT cautions for some fluoroquinolones.) FDA Access Data
7. Proton-pump inhibitor (e.g., omeprazole)—if reflux worsens cough/aspiration risk; follow FDA labeling. PMC
8. Laxatives/constipation plan—important when mobility falls or on opioids; use labeled OTCs as directed; prevents Valsalva strain in cardiomyopathy. PMC
9. Electrolyte-sparing diuretic alternative (eplerenone)—listed above; chosen when spironolactone side effects occur. FDA Access Data

---

Dietary molecular supplements

Supplements are not cures. Discuss with your clinician, especially if you have cardiomyopathy or take anticoagulants.

1. Creatine monohydrate: RCTs and meta-analyses in muscular dystrophies show modest strength gains and good tolerance in the short to medium term; common approach 3–5 g/day (some use a loading phase). Monitor kidneys and avoid if you have significant CKD. Cochrane+1

2. Vitamin D: supports bone/muscle health when deficient; typical replacement 800–2000 IU/day (per labs). Benefit is clearest in deficiency; very high doses can be harmful. PMC+1

3. Coenzyme Q10 (CoQ10): antioxidant role in muscle mitochondria; small studies in dystrophies suggest possible strength benefit; common doses 90–300 mg/day with fat-containing meals. Evidence is mixed. PMC+1

4. Omega-3 fatty acids: general heart-healthy effects; dose commonly 1–2 g/day EPA+DHA; may help lipids and inflammation but data in LGMD are sparse. (Use with anticoagulants only under advice.) PMC

5. Magnesium (for cramps): may help cramps in some people; dose and product individualized; watch diarrhea. Evidence limited in dystrophies. PMC

6. Protein optimization (whey/casein if needed): target daily protein appropriate for your weight and activity; helps maintain muscle mass with PT. renaissance.stonybrookmedicine.edu

7. L-carnitine: mechanistic rationale for fatty-acid transport; evidence in LGMD is limited; discuss before use. PMC

8. B-complex (esp. B12 if low): correct deficiencies that worsen fatigue or neuropathy symptoms; dose guided by labs. PMC

9. Antioxidant-rich diet (berries, leafy greens) rather than high-dose antioxidant pills; food-based approach is safest. PMC

10. Calcium (with vitamin D if low): supports bone health when mobility is reduced; dosing per age and labs to avoid excess. PMC

---

Immunity boosters, regenerative, and stem-cell drugs

There are no FDA-approved regenerative or stem-cell drugs for LGMDR7. Because they are unproven for this disease and may be risky or exploitative, I cannot list doses for such products. Safer, evidence-based ways to protect health include vaccinations, respiratory care, cardiac guideline-directed therapy, and enrollment in regulated clinical trials if available. PMC

---

Procedures/surgeries (when and why)

1. Pacemaker/ICD for significant conduction disease or life-threatening arrhythmias due to cardiomyopathy—decided by cardiology using guideline criteria. www.heart.org+1

2. Cardiac resynchronization therapy (CRT) in selected HF with wide QRS/LBBB to improve symptoms and outcomes. www.heart.org

3. Spinal surgery for severe scoliosis when curves impair breathing/sitting or cause pain. renaissance.stonybrookmedicine.edu

4. Tendon-lengthening (e.g., Achilles) for fixed contractures interfering with standing or bracing. renaissance.stonybrookmedicine.edu

5. Advanced HF therapies (LVAD/heart transplant) in end-stage cardiomyopathy after full medical therapy. PMC+1

---

Preventions

1. Yearly flu shot and age-appropriate pneumococcal vaccine. journal.chestnet.org

2. Avoid smoking; keep home air clean to reduce respiratory infections. journal.chestnet.org

3. Routine PT and stretching to limit contractures. renaissance.stonybrookmedicine.edu

4. Moderate, regular activity—avoid both overexertion and prolonged inactivity. renaissance.stonybrookmedicine.edu

5. Early cough help (assisted cough devices when needed). journal.chestnet.org

6. Sleep evaluation if snoring, morning headaches, or daytime sleepiness develop. journal.chestnet.org

7. Cardiac checkups even if you feel well; detect silent issues early. PMC

8. Fall-proof your home (rails, remove clutter). renaissance.stonybrookmedicine.edu

9. Maintain vitamin D and bone health to lower fracture risk. PMC

10. Carry a medication list (e.g., if on amiodarone or anticoagulants) to avoid interactions. FDA Access Data+1

---

When to see doctors (red flags)

See your neuromuscular team soon for: 1) new or rapid loss of walking ability; 2) increasing falls; 3) shortness of breath at rest or when lying flat; 4) morning headaches or daytime sleepiness; 5) chest pain, fainting, or palpitations; 6) new swallowing problems or weight loss; 7) swelling of legs/abdomen; 8) fever and cough producing colored phlegm; 9) severe cramps or pain not relieved by rest; 10) any medication side effects like dizziness, slow heartbeat, or bleeding. journal.chestnet.org+1

---

What to eat & what to avoid

1. Eat: balanced meals with lean protein to support muscles (fish, eggs, legumes). Avoid: crash diets that cause muscle loss. renaissance.stonybrookmedicine.edu

2. Eat: fruits/vegetables for antioxidants. Avoid: ultra-processed, high-salt foods (worsen edema/heart failure). PMC

3. Eat: enough calories to maintain weight for mobility. Avoid: excessive sugary drinks. PMC

4. Add: vitamin D (food/sunlight or supplements if low). Avoid: megadoses without lab checks. Wiley Online Library

5. Hydrate well to help cramps/stools. Avoid: dehydration. PMC

6. If on anticoagulants, keep vitamin K intake steady; consult your doctor. FDA Access Data

7. If on diuretics, include potassium-rich foods only if your doctor approves and labs allow. FDA Access Data

8. Limit alcohol (can worsen falls and interact with meds). PMC

9. If reflux or aspiration risk, smaller meals, avoid late-night eating, elevate head of bed. PMC

10. Consider creatine only after discussing with your clinician; choose reputable products. Cochrane

---

FAQs (fast, friendly answers)

1) Is there a cure?
No cure yet. Care focuses on safe exercise, breathing support, and heart protection. Clinical trials are ongoing for various LGMD pathways. Muscular Dystrophy Association

2) How is it inherited?
Autosomal recessive: both parents are usually carriers; each child has a 25% chance of being affected. Genetic counseling helps families plan. MedlinePlus

3) Does everyone get heart problems?
No. Some people with TCAP variants have cardiomyopathy; others do not. Regular heart checks are still wise. PMC

4) What exercise is safe?
Gentle, regular, sub-maximal activity guided by PT; avoid painful, high-intensity eccentric training. renaissance.stonybrookmedicine.edu

5) Will I need a ventilator?
Many people never do. If breathing muscles weaken, NIV at night can help a lot and improve quality of life. journal.chestnet.org

6) Are steroids helpful?
Unlike Duchenne, routine steroids are not standard for LGMDR7. They can harm bone and metabolic health; decisions are individualized. renaissance.stonybrookmedicine.edu

7) Which vitamins should I take?
Correct vitamin D deficiency; consider creatine after discussing with your clinician. Evidence for other supplements is limited/mixed. PMC+1

8) Can children be tested?
Yes—genetic testing confirms diagnosis and guides monitoring. A genetic counselor can advise on timing. renaissance.stonybrookmedicine.edu

9) What about stem-cell therapy abroad?
There is no approved stem-cell therapy for LGMDR7; unregulated treatments may be risky and expensive. Stick to clinical trials. PMC

10) How often should I have heart testing?
Your cardiologist will decide, but many people get ECG/echo at baseline and at regular intervals even if asymptomatic. PMC

11) Will I lose walking ability?
Progression varies widely. Early PT, stretching, falls prevention, and timely bracing help keep mobility longer. renaissance.stonybrookmedicine.edu

12) Can women with LGMDR7 have healthy pregnancies?
Many can with planning and cardiac/respiratory monitoring; involve high-risk OB and cardiology/neuromuscular teams. PMC

13) Why do I have morning headaches?
Possible night-time hypoventilation; ask about sleep testing and NIV. journal.chestnet.org

14) What if I get palpitations?
Seek prompt care; arrhythmias need ECG/Holter and treatment. Some patients need an ICD or pacemaker. www.heart.org

15) Where can I read more?
Orphanet and peer-reviewed studies on TCAP/telethonin and CHEST respiratory guidelines for neuromuscular disease are helpful. orpha.net+

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 09, 2025.

PDF Documents For This Disease Condition References